tbuckley/cabot-search huggingface dataset:
Abstract 2253: The association of Brugada pattern type 1 and fever: a retrospective analysis
Authors: Shepard D Weiner, Kirsten O Healy, James A Reiffel, James Coromilas
Journal: Circulation (2007)

INTRODUCTION: Many precipitants of the Brugada pattern ECG have been identified, including fever. However, the association of fever with Brugada pattern type is unknown. We assessed the hypothesis that the Brugada pattern ECGs that occur in the setting of a febrile episode are related to the Brugada pattern type. METHODS: This retrospective study examined all ECGs performed at Columbia University Medical Center from October 2004 to March 2007. The ECGs identified as showing possible Brugada pattern were reviewed and classified according to the ECG criteria endorsed by the Heart Rhythm Society and European Heart Rhythm Association. The medical record was then investigated for documentation of fever, defined as a temperature greater than or equal to 38.0 degrees Celsius. The primary outcome was the presence of fever within 48 hours of the Brugada pattern ECG. RESULTS: Forty Brugada pattern ECGs were identified (21 type 1 and 19 type 2). Background characteristics of the patients according to Brugada pattern type are shown in the Table . Eleven patients (27.5%) had fever (median temperature 38.4; temperature range 38.0 – 40.1) and Brugada pattern ECGs. There was a statistically significant association of Brugada pattern type 1 (nine patients) and fever compared to Brugada pattern type 2 (two patients) and fever (p=0.031; OR 6.96, 95% CI 1.26 – 38.44). Seven of nine patients (77.7%) with fever and Brugada pattern type 1 had a normal ECG when afebrile and one of two patients (50.0%) with fever and Brugada pattern type 2 had a normal ECG when afebrile. CONCLUSIONS: A significant number of patients with Brugada pattern type 1 had this ECG finding in the context of fever. The majority of these patients had a normal ECG when afebrile. Further investigation is needed to assess the biologic plausibility of this finding as well as the relationship of Brugada pattern type 1 unmasked by fever in asymptomatic patients to the clinical features of Brugada syndrome. Background Characteristics by Brugada Pattern Type
Abstract 386: A Novel Aquaretic and Glomerular Filtration Rate Enhancing Peptide Without Vascular Vasodilatory Actions in Experimental CHF.
Authors: Horng H Chen, ShuChong Pan, John C Burnett, Robert D Simari
Journal: Circulation (2007)

BACKGROUND: BNP is a cardiac peptide with vasodilatory, natriuretic and diuretic properties. Recent studies have suggested that its vasodilatory hypotensive properties may limit the renal actions of BNP, especially in patients with borderline low blood pressure. We have recently identified an alternatively spliced transcript for BNP (ASBNP) that includes a unique and distinct longer carboxyl-terminus consisting of 34 amino acids. Based upon preliminary studies, we generated a truncated form (ASBNP2.1) that contains the first 16 amino acids of the C-terminal of ASBNP. METHODS: We determined the cardiorenal and humoral actions of intravenous infusion of ASBNP2.1 at 2 pmol/Kg/min, 10 pmol/Kg/min and 100 pmol/Kg /min in 10 dogs with rapid ventricular pacing induced overt CHF (240 bpm for 10 days). * p&lt;0.05 RESULTS: IV infusion of ASBNP 2.1 increased aquaresis (from 0.19±0.04 to 0.32±0.07, 0.46±0.11 and 0.39±0.09 ml/min*) without a significant change in urinary sodium excretion. Importantly, ASBNP 2.1 enhanced glomerular filtration rate (GFR), from 31±4 to 47±8, 69±10 and 56±9 ml/min*. These renal actions were associated with increases in urinary BNP*, ANP* and cGMP* excretion. BNP 2.1 did not have any systemic vasodilatory action resulting in no change in mean arterial blood pressure or cardiac-filling pressures even at the highest dose. There was not change in serum sodium concentration. CONCLUSION: We report for the first time that this novel peptide based upon ASBNP has potent aquaretic and GFR enhancing actions without the vasodilatory hypotensive properties in an experimental model of overt CHF. The lack of vasodilatation but with renal actions also suggest that the C-terminus plays a key role in the vascular actions of this peptide offering new insights into vascular-renal structure function of BNP and related peptides. This renal specific peptide may have potential therapeutic benefit in states of renal dysfunction with volume overload to enhance GFR and water excretion without the detrimental side effect of hypotension.
Pumps and Catheters for Intrahepatic Artery Therapy
Authors: Joseph C. Bottino
Journal: Liver Cancer (1985)

Regional intra-arterial chemotherapy infusions depend entirely on the availability of sophisticated technology. The two major components of this technology are the infusion device and the intravascular access device. Unquestionably, the commercial production of intravascular infusion equipment has promoted the implementation of many clinical trials to explore the potential efficacy of regional chemotherapy. Often, the clinical talents necessary to deliver intra-arterial chemotherapy have in turn exerted substantial influence on the technological development of these devices. Many examples of infusor prototype changes dictated by clinical observation and requirements can be cited. As a result, the available technology has become increasingly flexible for both the patient and the investigator. The margin of safety and the ease of maintenance (if any at all is required) has greatly enlarged the pool of patients who are suitable candidates for this type of therapy. The modern investigator now has very few technological limitations in the choice of drugs and drug schedules. Furthermore, additional strategies for governing local gradients and drug concentrations are rapidly being developed. This chapter selectively reviews infusion and vascular access devices applicable for hepatic arterial chemotherapy infusions.KeywordsSilicone ElastomerHepatic Arterial Chemotherapy InfusionInfusion DeviceIntraarterial InfusionImplantable Drug DeliveryThese keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Set a Microbe to Kill a Microbe
Authors: Paul D Thacker
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Influence of Peripheral Arterial Disease on Outcomes
Authors: Jacqueline Saw, Deepak L. Bhatt, David J. Moliterno, Sorin J. Brener, Steven R. Steinhubl, A. Michael Lincoff, James E. Tcheng, Robert A. Harrington, Maarten Simoons, TingFei Hu, Mobeen A. Sheikh, Dean J. Kereiakes, Eric J. Topol
Journal: Journal of the American College of Cardiology (2006)
Abstract 6203: Central Pulse Pressure ≥50 mmHg Predicts Adverse Cardiovascular Outcome: The Strong Heart Study
Authors: Mary J Roman, Richard B Devereux, Jorge R Kizer, Peter M Okin, Elisa T Lee, Jason G Umans, Barbara V Howard
Journal: Circulation (2008)

Central (aortic) and brachial blood pressure differ as a consequence of pulse wave amplification and wave reflection. Central pressure more closely reflects the load placed on the left ventricle an...
Phase II trial of satraplatin (S) and paclitaxel (P) in first-line advanced non-small cell lung cancer (NSCLC) treatment: Final results
Authors: D. S. Thompson, D. R. Spigel, J. D. Hainsworth, S. F. Jones, H. A. Burris, L. Sade, E. Raefsky, F. A. Greco, S. Yun, M. Noursalehi
Journal: Journal of Clinical Oncology (2008)

19023 Background: In a prior phase I trial we combined a new oral platinum analogue (S) with P in patients (pts) with refractory malignancies, and found this regimen to be safe (Invest New Drugs 20: 55–61, 2002). In this multicenter phase II trial we evaluated S and P in pts with newly diagnosed advanced NSCLC. Methods: This was a single stage trial with a primary objective to achieve an overall response rate (ORR) of 30% (α .05, β .10). Pts with previously untreated unresectable stage IIIB/IV NSCLC, measurable disease, ECOG PS 0–2, and signed informed consent were eligible. All pts received: S 80mg/m2 PO days (D) 1–5 and P 200mg/m2 IV D 1 every 28D for up to 6 cycles. After an interim analysis found grade 3/4 neutropenia in 41% (n=22) S was reduced to 70mg/m2. Pts were restaged every 8 weeks (per RECIST criteria). Results: 38 pts were enrolled from 2/06 to 4/07, with a median follow-up of 5.4 months (range 0.3 - 17.1 months). Baseline characteristics: median age 67 years (range 49 - 90 years); male 63%; ECOG PS 0 - 1, 86%; non-squamous/not otherwise specified, 33%/33%. There was 1 complete and 6 partial responses for an ORR of 21% (95% CI 9% - 39%). 8 pts (24%) had stable disease and 14 pts (42%) had progressive disease. 9 pts were not evaluable due to: treatment- related toxicity, 4 pts (included in ORR denominator); data unconfirmed, 3 pts; never received treatment, 1 pt; and pt preference, 1 pt. Grade (G) 3/4 toxicity in >2 pts was limited to: abdominal pain (16%), anorexia (14%), diarrhea (8%), neutropenia (27%), and thrombocytopenia (19%). 3 pts (8%) developed severe febrile neutropenia. 1 pt died form an aortic thrombosis, possibly treatment-related. The median time to progression is 4.2 months for evaluable patients, however median survival time is not estimable as there are very few deaths reported at this time. Conclusions: The SP regimen was well tolerated and associated with limited G 3/4 toxicity when S was administered at 70mg/m2every 28D. S appears to have activity that is similar to other platinum agents when combined with P in upfront NSCLC treatment. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration GPC Biotech Bayer, Genentech GPC Biotech Bristol-Myers Squibb, Eli Lilly and Company, Genentech, GlaxoSmithKline, GPC Biotech, sanofi-aventis
Abstract 12134: Treatment of Multi-Vessel Coronary Artery Disease (CAD) in Primary Percutaneous Coronary Intervention (PPCI) for ST segment Elevation Myocardial Infarction (STEMI): Culprit Only Revascularization is Associated with Higher Major Adverse Cardiovascular Event (MACE) Rates
Authors: Mohammed M Akhtar, Adam Graham, Daniel Jones, Krishna Rathod, S Gallagher, Ajay Jain, Sam Mohiddin, Charles Knight, Anthony Mathur, Andrew Wragg
Journal: Circulation (2011)

Background: Multivessel disease occurs in 40-65% of patients undergoing PPCI for STEMI and is associated with poor prognosis. Guidelines recommend treating the culprit artery alone during PPCI. The...
Plasma Lipoprotein Induction and Suppression of the Generation of Cellular Procoagulant Activity In Vitro
Authors: Bradford S. Schwartz, Gary A. Levy, Linda K. Curtiss, Daryl S. Fair, Thomas S. Edgington
Journal: Journal of Clinical Investigation (1981)

In the process of analyzing the effects of lipoproteins on functions of lymphoid cells, it was observed that physiological concentrations of isolated human plasma lipoproteins possess varying capacities to rapidly enhance the expression of procoagulant activity of human peripheral blood mononuclear cells in vitro. In a strict dose-dependent fashion, very low density lipoprotein, intermediate density lipoprotein, and high density lipoprotein enhanced both the surface expression by viable cells and the total cellular content of procoagulant activity during a 6-h incubation. Very low density lipoprotein induced a maximal 6.7-fold increase in the expression of a thromboplastin activity, which was consistent with tissue factor, in that it was dependent on Factors VII, X, and II. Both intermediate density lipoprotein and high density lipoprotein induced approximately a 12-fold increase of a different procoagulant activity which appears to be a direct prothrombin activator. This prothrombinase was calcium dependent and was inhibited by 2.5 mM diisopropylfluorophosphate, but was not neutralized by anti-Factor X antibodies or by inhibitors of Factor Xa. In contrast to the other lipoprotein density classes, low density lipoprotein did not stimulate procoagulant activity, but instead actively suppressed the generation of the two procoagulant activities induced by the stimulatory lipoproteins. Suppression by low density lipoprotein was clearly evident at molar ratios of low density lipoprotein to stimulatory lipoproteins of 1:3 or less. Reconstitution of all lipoproteins to physiological concentrations was not stimulatory as a consequence of the suppressive effects of low density lipoprotein. These data indicate that isolated plasma lipoproteins are capable of regulating the expression of two different procoagulant activities of peripheral blood mononuclear cells in vitro. The possibility that these interactions may be implicated in the association between certain types of hyperlipoproteinemias and thromboembolic disease merits study.
A novel CX3CR1 antagonist eluting stent reduces stenosis by targeting inflammation
Authors: Mohammed T. Ali, Kenneth Martin, Arun H.S. Kumar, Erika Cavallin, Stefan Pierrou, Birgitta M. Gleeson, William L. McPheat, Elizebeth C. Turner, Chien-Ling Huang, Wisam Khider, Carl Vaughan, Noel M. Caplice
Journal: Biomaterials (2015)
Predictors of Complete Heart Block After Transcoronary Ablation of Septal Hypertrophy
Authors: Thorsten Lawrenz, Frank Lieder, Markus Bartelsmeier, Christian Leuner, Bianca Borchert, Dorothee Meyer zu Vilsendorf, Claudia Strunk-Mueller, Jens Reinhardt, Andre Feuchtl, Christoph Stellbrink, Horst Kuhn
Journal: Journal of the American College of Cardiology (2007)
Abstract 13417: IGF-1 Enhances Expression of iPS Cell Reprogramming Factors and Telomerase activities in Human Dermal Fibroblasts: A potential Role for IGF-1 in Induction of Pluripotent Stem Cells and Antisenescence
Authors: Yangxin Li, Harnath Shelat, Song Gao, Hanjing Wu, Man Zhu, Jiaming Xu, Yong-Jian Geng
Journal: Circulation (2010)
Atropine or Glycopyrrolate with Neostigmine 5 mg: A Comparative Dose-Response Study
Authors: M G Salem, R S Ahearn
Journal: Journal of the Royal Society of Medicine (1986)

One hundred and fifteen patients, separated into 4 groups, received neostigmine 5 mg with either atropine 1.2 mg or 1.8 mg, or glycopyrrolate 0.6 mg or 0.9 mg. Those receiving 0.9 mg glycopyrrolate had insignificant changes in heart rate in the immediate postreversal period. It is recommended that when glycopyrrolate is used with 5 mg neostigmine, the optimum dose is 0.9 mg.
Preclinical and Clinical Resistance Mechanisms To The Investigational Selective FLT3 Inhibitor PLX3397 In FLT3-ITD+ Acute Myeloid Leukemia (AML)
Authors: Catherine C Smith, Kimberly Lin, Elisabeth Lasater, Whitney Stewart, Lauren E Damon, Andrew Kasarskis, Ali Bashir, Matthew Pendleton, Robert Sebra, Alexander E Perl, Mai H Le, Chao Zhang, Brian West, Neil P. Shah
Journal: Blood (2013)
A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2+ metastatic breast cancer (MBC)
Authors: H. S. Rugo, S. Franco, P. Munster, A. Stopeck, W. Ma, J. Lyandres, S. Lahiri, M. Arbushites, M. Koehler, M. N. Dickler
Journal: Journal of Clinical Oncology (2008)

1042 Background: In a preclinical HER2+ BC model, combination anti-HER2 and anti-VEGF therapy was more effective than either treatment alone, and increased VEGF expression is associated with worse outcome in HER2+ disease. B plus trastuzumab (T) has shown promising activity in patients (pts) with HER2+ MBC, however the cardiac toxicity of this regimen requires further evaluation. L, an oral dual inhibitor of EGFR and HER2, is approved in combination with capecitabine after T-based therapy for HER2+ MBC. L may have less cardiac toxicity and may be a safer and more effective alternative to T+B. This hypothesis was evaluated in a phase 2 trial of L+B in HER2+ MBC pts. Methods: This 50-patient single-arm study evaluated L (1,500 mg PO daily) plus B (10 mg/kg IV q2wk). The primary endpoint is progression-free survival (PFS) at 12 weeks with 84% power to detect a clinically significant PFS rate of 60%; secondary endpoints include toxicity and response per RECIST. Efficacy was assessed at Week 6, 12, and q12wks thereafter. HER2+ status was locally defined as HER2 FISH amplified or IHC3+. Serial evaluation of circulating tumor and endothelial cells and HER2 extracellular domain was performed. Results: Presently 31 pts are enrolled with a median of 4 prior MBC therapies (range 0–13); 30/31 received prior T (median duration 84 weeks, 14–250 weeks). The most commonly-reported AEs included diarrhea (61%), muscle pain (48%), fatigue (39%), nausea (28%), and emesis (29%). Two grade 2 asymptomatic LVEF decreases and one grade 3 GI hemorrhage were reported. At week 12, 16/21 patients were evaluable for efficacy; 3 pts had a partial response (PR), 10 pts had stable disease (SD), and 3 pts had progressive disease (PD), resulting in a 12-week PFS rate of 62%. At week 24, 5/9 (56%) pts have shown clinical benefit (CR, PR, SD ≥ 24 weeks); 2/2 pts remain in PR after 36 weeks. Conclusions: L+ B is well tolerated and has shown promising activity in heavily pretreated HER2+ MBC pts. Updated results from this ongoing trial will be reported. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration GlaxoSmithKline Genentech, GlaxoSmithKline GlaxoSmithKline AstraZeneca, Genentech, Genomic Health, GlaxoSmithKline Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Novarits, Pfizer, Roche, sanofi-aventis
Abstract 17335: Visual or Tactile Feedback: Which One is More Important for Catheter Ablation?
Authors: Luigi Di Biase, Prasant Mohanty, Vivek Reddy, Pierre Jais, Javier Sanchez, Rodney Horton, G. Joseph Gallinghouse, Shane Bailey, Sergio Conti, Alex Goldenberg, Aditi Garg, Aaron Grogan, Daniel T. Wallace, Michelle Haissaguerre, Andrea Natale
Journal: Circulation (2010)

Introduction: Contact Force between the ablation electrode and the targeted tissue is important in determining lesion size. Visual and tactile feedbacks together are clinically used to assess cathe...
Hypercholesterolemia and Metabolic Syndrome: Mischievous Partners
Authors: Scott M. Grundy
Journal: Circulation (2013)

Elevations of two lipoproteins contribute to atherogenic hypercholesterolemia: low density lipoprotein (LDL) and very low density lipoprotein (VLDL). Their atherogenic potential is identified by their cholesterol (C) content. Together they constitute non-HDL-C. In populations and individuals having very low levels of non-HDL-C, atherosclerotic cardiovascular disease (ASCVD) is rare. In persons with severe elevations of non-HDL-C, these lipoproteins can initiate atherogenesis and precipitate ASCVD in the absence of other risk factors. The importance of non-HDL-C for development of ASCVD is dramatically shown by the reduction in risk accompanying cholesterol-lowering therapy. This does not negate the importance of other risk factors. The most common aggregation of these risk factors occurs in a condition called the metabolic syndrome. The prevalence of the metabolic syndrome increases in parallel with the increasing obesity in the population. This condition is characterized by abdominal obesity, insulin resistance and increased risk for type 2 diabetes, elevations in triglycerides, reduction in HDL, elevations in blood pressure, and prothrombotic and proinflammatory states. Epidemiological studies shown that the presence of the metabolic syndrome doubles the risk for ASCVD and carries a 5-fold increase in risk for type 2 diabetes. Most of the metabolic syndrome can be attributed to lifestyle factors, notably, over nutrition and decreased physical activity. Future advances on prevention of ASCVD will depend on new approaches to controlling hypercholesterolemia and to reducing the prevalence of the metabolic syndrome.
Rights, wrongs, and the dilemma of coerced community treatment
Authors: J L Geller
Journal: American Journal of Psychiatry (1986)

An outpatient treatment approach directed to patients with histories of psychotically based dangerousness, poor compliance, and recidivism is described. Cases are presented that suggest favorable outcomes of this approach, but the coercive nature of the treatment raises questions about the psychiatrist's violation of patients' rights and transgression of ethical standards. If psychiatrists are to successfully treat the most difficult chronic patients, can we do it without legally sanctioned, benevolent, coercive treatments? One model of such treatment is outpatient commitment. There is concern that without sound outpatient commitment statutes, we may witness the reemergence of asylums.
Abstract 1364: Not All Refractory Period Abbreviation Promotes Atrial Fibrillation Equally: A Comparison Between Vagal and Atrial Tachycardia Remodeled Substrates
Authors: Grigorios Katsouras, Masao Sakabe, Kristina Lemola, Philippe Comtois, Michael Ting, Ange Maguy, Brett Burstein, Mario Talajic, Peter Guerra, Stanley Nattel
Journal: Circulation (2007)

Background: Vagal (VG) and atrial tachycardia remodeled (ATR) AF substrates share many features: reduced effective refractory period (ERP), increased ERP heterogeneity and some common molecular mechanisms (I KACh enhancement by acetylcholine release in VG, constitutive I KACh enhancement in ATR). This study compared VG and ATR substrates at comparable ERP abbreviation. Methods: In each of 5 VG dogs, bilateral cervical VG stimulation parameters were adjusted (mean±SD: 3.6±1.7 V and 12.2±1.5 Hz; 0.2 ms) to produce the same mean ERP (at 4 RA and 4 LA sites) as a sex and weight matched ATR dog (RA paced 400 bpm × 7 days). Mean duration of burst pacing induced AF (DAF) and local dominant frequencies (DFs, analyzed by FFT at 240 bipolar electrodes, Fig A ) were determined. Results: Mean ERP was 79±13 ms in VG and 78±13 ms in ATR dogs. DAF was greater in VG than ATR dogs (1056±323 vs 289±510 s *P&lt;0.01; both significantly &gt; control, 43±61 s). Despite matched ERPs, there were significant differences in DF distribution (Fig B ): DF was faster (mean DF: 11.8±1.1 Hz VG vs 9.7±1.3 Hz ATR*) and DF variability greater (indicated by SD: 1.8±0.6 Hz VG vs 0.8±0.5 Hz ATR*) in VG dogs. AF drivers reflected by maximum DF zones were adjacent to autonomic ganglia (over RA in 4/5) for VG dogs; in ATR dogs driver zones were less clear and showed variable location. Conclusions: For a comparable atrial ERP, VG AF is faster and more persistent than AF with an ATR substrate. These results are consist with modeling work suggesting that VG-induced hyperpolarization is an important contributor to AF-maintaining rotor stabilization and acceleration, and indicate important differences between these superficially similar AF substrates.
Abstract 3321: Characterization of Fibrofatty Scar in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: Concordance Between Contrast-Enhanced Cardiac Magnetic Resonance and 3-D Electroanatomic Voltage Mapping
Authors: Martina Perazzolo Marra, Domenico Corrado, Luisa Cacciavillani, Francesco Corbetti, Federico Migliore, Loira Leoni, Angelo Ramondo, Barbara Bauce, Cristina Basso, Andrea Nava, Luciano Daliento, Gianfranco Buja, Gaetano Thiene, Sabino Iliceto
Journal: Circulation (2006)